← Who reports today · Health Care
How Charles River Laboratories (CRL) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · quarter ended 06/27/2026 · reported 08/05/2026
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. · Text: Wikipedia, CC BY-SA 4.0, abridged
More about the company
Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
How does Charles River Laboratories make money?
Charles River Laboratories brought in $1.00 billion of revenue in Q2 2026, down 2.7% year over year. The largest source was Service revenue: $808 million, or 81% of the total, followed by Product revenue ($196M, 20%).
Revenue by source, Q2 2026
- Service revenue$808M · 81% · −3.9%
- Product revenue$196M · 20% · +2.3%
Shares of $1.00B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is CRL’s next earnings date?
Wednesday, November 4, 2026estimated
Expected around Nov 4 — based on last year’s report on Nov 5, 2025. We have not yet seen the company's announcement of the date.
How we estimate
The estimate is the date of the same-quarter report a year ago, per the company’s SEC filing, moved forward 52 weeks (same weekday). Companies usually keep the same week; the date will be replaced once CRL announces it.
Same quarter a year ago (ended September 27, 2025): revenue $1.005B, EPS (GAAP) $1.10
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
What time does CRL report? Usually before market open: the last 4 results releases reached the SEC at 7:15 am, 7:14 am, 7:13 am, 8:10 am ET.
Last report: Aug 5, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates: company announcements; past dates and times — SEC 8-K filings. Who else reports this week →
All figures in $M.
Verdict: revenue fell 2.7% y/y to $1.00B, operating margin 11.9% vs 9.7%, net loss $1.5M (vs net income $52.3M a year earlier).
Source and notation
Source: Charles River Laboratories International press release, 8-K EX-99.1 of 08/05/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Heads-up
- a net loss in Q2 2026 ($1.5 · vs $52.3)
Most likely because the effective tax rate was 101.4% vs 26.2% a year earlier; operating income was $120M, a 11.9% margin vs 9.7% a year earlier; costs grew faster than revenue (selling, general and administrative +20% y/y, less: net income attributable to noncontrolling interests +97% y/y). Based on the Q2 2026 report.
The company's report ↗CRL earnings history: past report dates
| Aug 5, 2026 Wed | 7:15 ambefore market open | Jun 27, 2026 | $1.0B−3% y/y | −$0.03 |
| May 7, 2026 Thu | 7:14 ambefore market open | Mar 28, 2026 | $996M+1% y/y | −$0.30 |
| Jan 13, 2026 Tue | 8:10 ambefore market open | Dec 27, 2025 | ≈$994M−1% y/y | ≈−$5.57−34% y/y |
| Nov 5, 2025 Wed | 7:16 ambefore market open | Sep 27, 2025 | $1.0B−0% y/y | $1.10−17% y/y |
| Aug 6, 2025 Wed | 7:08 ambefore market open | Jun 28, 2025 | $1.0B+1% y/y | $1.06−39% y/y |
| May 7, 2025 Wed | 7:08 ambefore market open | Mar 29, 2025 | $984M−3% y/y | $0.50−62% y/y |
| Feb 19, 2025 Wed | 7:19 ambefore market open | Dec 28, 2024 | ≈$1.0B−1% y/y | ≈−$4.17 |
| Nov 6, 2024 Wed | 7:21 ambefore market open | Sep 28, 2024 | $1.0B−2% y/y | $1.33−21% y/y |
| Aug 7, 2024 Wed | 7:21 ambefore market open | Jun 29, 2024 | $1.0B−3% y/y | $1.74−8% y/y |
| May 9, 2024 Thu | 7:31 ambefore market open | Mar 30, 2024 | $1.0B−2% y/y | $1.30−35% y/y |
| Feb 14, 2024 Wed | 7:30 ambefore market open | Dec 30, 2023 | ≈$1.0B−8% y/y | ≈$3.63−1% y/y |
| Nov 8, 2023 Wed | 7:30 ambefore market open | Sep 30, 2023 | $1.0B+4% y/y | $1.69−10% y/y |
| Aug 9, 2023 Wed | 7:30 ambefore market open | Jul 1, 2023 | $1.1B+9% y/y | $1.89−11% y/y |
| May 11, 2023 Thu | 7:30 ambefore market open | Apr 1, 2023 | $1.0B+13% y/y | $2.01+11% y/y |
| Feb 22, 2023 Wed | 7:30 ambefore market open | Dec 31, 2022 | ≈$1.1B+22% y/y | ≈$3.65+37% y/y |
Show all 15 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Charles River Laboratories: 15-year financials
| 2025 | 4,015 | 25.2 | −144 | 519 |
| 2024 | 4,050 | 227 | 22.2 | 502 |
| 2023 | 4,129 | 617 | 475 | 365 |
| 2022 | 3,976 | 651 | 486 | 295 |
| 2021 | 3,540 | 590 | 391 | 532 |
| 2020 | 2,924 | 433 | 364 | 380 |
| 2019 | 2,621 | 351 | 252 | 340 |
| 2018 | 2,266 | 331 | 226 | 301 |
| 2017 | 1,858 | 288 | 123 | 236 |
| 2016 | 1,681 | 238 | 155 | 262 |
| 2015 | 1,363 | 206 | 149 | 244 |
| 2014 | 1,298 | 178 | 127 | 195 |
| 2013 | 1,166 | 151 | 103 | 170 |
| 2012 | 1,130 | 166 | 97.3 | 161 |
| 2011 | 1,143 | 174 | 110 | 158 |
Show all 15 yearsShow fewer
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Shareholders’ equity at Jun 27, 2026: $2.8B (38% of total assets). Compare with other S&P 500 companies →
Charles River Laboratories (CRL) earnings: FAQ
How does Charles River Laboratories make money?
Charles River Laboratories brought in $1.00 billion of revenue in Q2 2026, down 2.7% year over year. The largest source was Service revenue: $808 million, or 81% of the total, followed by Product revenue ($196M, 20%).
When is CRL's next earnings date?
We have not yet seen an announcement of the date from Charles River Laboratories (CRL). Based on last year's report on Nov 5, 2025, the next report is expected around Nov 4, 2026.
What time does CRL report earnings?
Charles River Laboratories usually reports before market open: its latest results release was filed with the SEC at 7:15 am ET on Aug 5, 2026.
When did CRL last report earnings?
Charles River Laboratories reported Q2 2026 results on Aug 5, 2026.
Where can I find Charles River Laboratories's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to CRL's filings; this page breaks the latest report down in a Sankey chart.
How has Charles River Laboratories's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.5x: $1,143M in 2011 and $4,015M in 2025. The peak was $4,129M in 2023. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report — two independent automated readings of the release had to match, and every number in the text was checked against it. Figures checked against the filing on 10/16/2026. How we make the breakdowns · Report an error
More reports: CVS · Q2 2026 · DGX · Q2 2026 · DHR · Q2 2026 · DVA · Q2 2026 · DXCM · Q2 2026 · ELV · Q2 2026 · EW · Q2 2026 · GEHC · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · all reports